Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axatilimab +/- Ruxolitinib in MF and CMML
NCT07128381Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2026
- Primary completion
- Jul 2031
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of axatilimab in myelofibrosis (MF), chronic myelomonocytic leukemia (CMML), sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2026; status: recruiting.
02
Drugs
axatilimab
03
Conditions
myelofibrosis (MF)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT07128381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07128381.